Myonexus Therapeutics
Columbus
About Myonexus Therapeutics
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a global leader in muscular dystrophy gene therapy discovery and translational research.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $62.5M
- Funding stage: M&A
- Last round: Corporate Round (May 2018)
- Website: myonexustx.com
- Phone: 614.477.5445
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/myonexus-therapeutics-122737 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.